drug
EVRYSDI
Marketedupdated 3mo agoby Genentech Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4all catalysts(16)
approval · 16
Aug 7, 2020
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→
Apr 30, 2021
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→
May 27, 2022
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→
May 27, 2022
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→
Sep 21, 2022
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→
Mar 24, 2023
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→
Oct 3, 2023
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→
Feb 29, 2024
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→
Sep 17, 2024
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→
Feb 11, 2025
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→
Feb 11, 2025
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→
Jan 21, 2026
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→
Jan 21, 2026
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→
Jan 21, 2026
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→
Feb 10, 2026
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→
Feb 10, 2026
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→
Trials studying EVRYSDI
- phase4Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)
- phase4A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
- phase2A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
- phase4A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
- phase2A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy
- phase2A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
- phase3A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy
- —Investigating NMJ Defects in SMA Following Central and Peripheral SMN Restoration
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 3, 2026
44 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (13)
- Apr 15, 2041compositionUS 12122789
- Apr 15, 2041compositionUS 12122789
- Oct 4, 2038method-of-use (U-1943)US 11534444
- Oct 4, 2038method-of-use (U-1943)US 11534444
- Oct 1, 2038method-of-use (U-1943)US 12350273
- Oct 1, 2038method-of-use (U-1943)US 12350273
- Nov 8, 2036formulationUS 11938136
- Jan 25, 2036method-of-use (U-1943)US 11827646
- Jan 25, 2036method-of-use (U-1943)US 11827646
- May 11, 2035compositionUS 9969754
- May 11, 2035compositionUS 9969754
- Feb 8, 2033compositionUS 9586955
- Feb 8, 2033compositionUS 9586955
FDA exclusivities (4)
- May 27, 2029ODE-400Orphan Drug (7y)2.8y
- Aug 7, 2027ODE-334Orphan Drug (7y)352d
- Oct 3, 2026M-270Method (3y)44d
- Oct 3, 2026M-270Method (3y)44d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that